We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Sepsis Test Uses Magnetic Nanoparticles to Detect Bacterial Pathogens

By LabMedica International staff writers
Posted on 24 Aug 2023

When it comes to life-threatening blood poisoning caused by staphylococcus bacteria, quick identification of the bacteria in the bloodstream is vital to begin life-saving treatment. More...

This urgency stems from the fact that staphylococcal sepsis results in fatality for up to 40% of cases. The infection, triggered by spherical bacteria, might initially manifest as a local skin ailment or pneumonia. However, when staphylococci infiltrate the bloodstream during sepsis, severe complications can emerge. In such critical scenarios, prompt identification of pathogens and selection of suitable antibiotics are vital. This is especially crucial as Staphylococcus aureus strains can exhibit resistance to multiple antibiotics. Researchers have now developed "sepsis sensors" using magnetic nanoparticles that enable rapid detection of bacterial pathogens and identification of appropriate antibiotic candidates.

Researchers at Empa (Dübendorf, Switzerland), along with their colleagues from ETH Zurich (Zürich, Switzerland), looked for a way to bypass the lengthy intermediate step of first cultivating the bacteria in a blood sample for a diagnostic procedure. They developed a method utilizing magnetic nanoparticles that are capable of binding to staphylococci. Consequently, these bacteria can be identified through the application of a magnetic field. Subsequently, antibiotic sensitivity is assessed using a chemiluminescence technique. If antibiotic-resistant bacteria are present in the sample, it emits light. Conversely, if the bacteria can be eradicated with antibiotics, the reaction vessel remains dark.

Another problematic bacterial entity is Pseudomonas aeruginosa, a rod-shaped bacterium capable of causing various illnesses, including urinary tract infections via catheterization during hospital stays. Such infections can develop into sepsis, and these pathogens are often resistant to numerous antibiotics. In such cases, magnetic nanoparticles offer the distinct advantage of versatility. The approach can be customized for different bacteria types, similar to a modular system. This adaptability enabled the researchers to design a rapid "sepsis sensor" leveraging magnetic nanoparticles. In samples containing synthetic urine, this method reliably identified bacterial species and gauged potential antibiotic resistance through chemiluminescence reactions. So far, the researchers have assessed their magnetic nanoparticle toolkit for sepsis and urinary tract infections using laboratory samples. In the coming phase, the team plans to validate the sepsis tests alongside their clinical partners by analyzing patient samples.

"All in all, the sepsis test takes around three hours – compared to several days for a classic cultivation of bacterial cultures," said Empa researcher Fei Pan.

Related Links:
Empa 
ETH Zurich 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.